Sputnik V tech unsuitable for commercial manufacturing
Hyderabad’s Dr Reddy’s Laboratories has inked a distribution deal with Russian Direct Investment Fund (RDIF) for Sputnik V, but Indian players in talks with RDIF say the technology is not suited for commercial manufacturing.
It is also learnt that players like Indian Immunologicals (IIL) have opted out of the talks for manufacturing in India. The same could not be immediately verified with the company. According to sources, firms like Serum Institute, Biological E, Zydus Cadila, and IIL were in talks with RDIF.
According to Tass, in the past one month, over 3,000 Muscovites have received the Sputnik V jab.